dc.contributor.author | Gonzalez Malagon, SG | |
dc.contributor.author | Lopez Muñoz, AM | |
dc.contributor.author | Doro, D | |
dc.contributor.author | Bolger, TG | |
dc.contributor.author | Poon, E | |
dc.contributor.author | Tucker, ER | |
dc.contributor.author | Adel Al-Lami, H | |
dc.contributor.author | Krause, M | |
dc.contributor.author | Phiel, CJ | |
dc.contributor.author | Chesler, L | |
dc.contributor.author | Liu, KJ | |
dc.date.accessioned | 2018-03-16T10:01:25Z | |
dc.date.issued | 2018-03-19 | |
dc.identifier.citation | Nature communications, 2018, 9 (1), pp. 1126 - ? | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1595 | |
dc.identifier.eissn | 2041-1723 | |
dc.identifier.doi | 10.1038/s41467-018-03512-5 | |
dc.description.abstract | Neural crest migration is critical to its physiological function. Mechanisms controlling mammalian neural crest migration are comparatively unknown, due to difficulties accessing this cell population in vivo. Here we report requirements of glycogen synthase kinase 3 (GSK3) in regulating the neural crest in Xenopus and mouse models. We demonstrate that GSK3 is tyrosine phosphorylated (pY) in mouse neural crest cells and that loss of GSK3 leads to increased pFAK and misregulation of Rac1 and lamellipodin, key regulators of cell migration. Genetic reduction of GSK3 results in failure of migration. We find that pY-GSK3 phosphorylation depends on anaplastic lymphoma kinase (ALK), a protein associated with neuroblastoma. Consistent with this, neuroblastoma cells with increased ALK activity express high levels of pY-GSK3, and blockade of GSK3 or ALK can affect migration of these cells. Altogether, this work identifies a role for GSK3 in cell migration during neural crest development and cancer. | |
dc.format | Electronic | |
dc.format.extent | 1126 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Cell Line, Tumor | |
dc.subject | Neural Crest | |
dc.subject | Animals | |
dc.subject | Mice, Knockout | |
dc.subject | Xenopus laevis | |
dc.subject | Humans | |
dc.subject | Mice | |
dc.subject | Neuroblastoma | |
dc.subject | Glycogen Synthase Kinase 3 | |
dc.subject | Xenopus Proteins | |
dc.subject | Cell Movement | |
dc.subject | Phosphorylation | |
dc.subject | Cell Lineage | |
dc.subject | Pregnancy | |
dc.subject | Female | |
dc.subject | Glycogen Synthase Kinase 3 beta | |
dc.subject | Anaplastic Lymphoma Kinase | |
dc.title | Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-02-20 | |
rioxxterms.versionofrecord | 10.1038/s41467-018-03512-5 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-03-19 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Nature communications | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Paediatric Solid Tumour Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Paediatric Solid Tumour Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Paediatric Solid Tumour Biology and Therapeutics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Paediatric Solid Tumour Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Paediatric Solid Tumour Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Paediatric Solid Tumour Biology and Therapeutics | |
pubs.publication-status | Published | |
pubs.volume | 9 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Paediatric Solid Tumour Biology and Therapeutics | |
dc.contributor.icrauthor | Poon, Evon | |
dc.contributor.icrauthor | Chesler, Louis | |